tetano
Editor, Senior Moderator
J Clin Lipidol
. 2021 Aug 10;S1933-2874(21)00122-7.
doi: 10.1016/j.jacl.2021.08.002. Online ahead of print.
Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19
Wen Dai[SUP] 1 [/SUP], Hayley Lund[SUP] 2 [/SUP], Yiliang Chen[SUP] 3 [/SUP], Jue Zhang[SUP] 1 [/SUP], Kristen Osinski[SUP] 4 [/SUP], Stephanie Zellner Jones[SUP] 1 [/SUP], Lisa Baumann Kreuziger[SUP] 5 [/SUP], José A López[SUP] 6 [/SUP], Ivor J Benjamin[SUP] 7 [/SUP], Roy L Silverstein[SUP] 3 [/SUP], Ze Zheng[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Alteration in blood triglyceride levels have been found in patients with coronavirus disease 2019 (COVID-19). However, the association between hypertriglyceridemia and mortality in COVID-19 patients is unknown.
Objective: To investigate the association between alteration in triglyceride level and mortality in hospitalized COVID-19 patients.
Methods: We conducted a retrospective study of 600 hospitalized patients with COVID-19 diagnosis (ICD10CM:U07.1) and/or SARS-CoV-2 positive testing results between March 1, 2020 and December 21, 2020 at a tertiary academic medical center in Milwaukee, Wisconsin. De-identified data, including demographics, medical history, and blood triglyceride levels were collected and analyzed. Of the 600 patients, 109 patients died. The triglyceride value on admission was considered the baseline and the peak was defined as the highest level reported during the entire period of hospitalization. Hypertriglyceridemia was defined as greater than 150 mg/dl. Logistic regression analyses were performed to evaluate the association between hypertriglyceridemia and mortality.
Results: There was no significant difference in baseline triglyceride levels between non-survivors (n = 109) and survivors (n = 491) [Median 127 vs. 113 mg/dl, p = 0.213]. However, the non-survivors had significantly higher peak triglyceride levels during hospitalization [Median 179 vs. 134 mg/dl, p < 0.001]. Importantly, hypertriglyceridemia independently associated with mortality [odds ratio=2.3 (95% CI: 1.4-3.7, p = 0.001)], after adjusting for age, gender, obesity, history of hypertension and diabetes, high CRP, high leukocyte count and glucocorticoid treatment in a multivariable logistic regression model.
Conclusions: Hypertriglyceridemia during hospitalization is independently associated with 2.3 times higher mortality in COVID-19 patients. Prospective studies are needed to independently validate this retrospective analysis.
Keywords: COVID-19 mortality; CRP; Diabetes; Inflammation; Leukocyte count; Obesity; Triglyceride; glucocorticoid.
. 2021 Aug 10;S1933-2874(21)00122-7.
doi: 10.1016/j.jacl.2021.08.002. Online ahead of print.
Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19
Wen Dai[SUP] 1 [/SUP], Hayley Lund[SUP] 2 [/SUP], Yiliang Chen[SUP] 3 [/SUP], Jue Zhang[SUP] 1 [/SUP], Kristen Osinski[SUP] 4 [/SUP], Stephanie Zellner Jones[SUP] 1 [/SUP], Lisa Baumann Kreuziger[SUP] 5 [/SUP], José A López[SUP] 6 [/SUP], Ivor J Benjamin[SUP] 7 [/SUP], Roy L Silverstein[SUP] 3 [/SUP], Ze Zheng[SUP] 8 [/SUP]
Affiliations
- PMID: 34470719
- DOI: 10.1016/j.jacl.2021.08.002
Abstract
Background: Alteration in blood triglyceride levels have been found in patients with coronavirus disease 2019 (COVID-19). However, the association between hypertriglyceridemia and mortality in COVID-19 patients is unknown.
Objective: To investigate the association between alteration in triglyceride level and mortality in hospitalized COVID-19 patients.
Methods: We conducted a retrospective study of 600 hospitalized patients with COVID-19 diagnosis (ICD10CM:U07.1) and/or SARS-CoV-2 positive testing results between March 1, 2020 and December 21, 2020 at a tertiary academic medical center in Milwaukee, Wisconsin. De-identified data, including demographics, medical history, and blood triglyceride levels were collected and analyzed. Of the 600 patients, 109 patients died. The triglyceride value on admission was considered the baseline and the peak was defined as the highest level reported during the entire period of hospitalization. Hypertriglyceridemia was defined as greater than 150 mg/dl. Logistic regression analyses were performed to evaluate the association between hypertriglyceridemia and mortality.
Results: There was no significant difference in baseline triglyceride levels between non-survivors (n = 109) and survivors (n = 491) [Median 127 vs. 113 mg/dl, p = 0.213]. However, the non-survivors had significantly higher peak triglyceride levels during hospitalization [Median 179 vs. 134 mg/dl, p < 0.001]. Importantly, hypertriglyceridemia independently associated with mortality [odds ratio=2.3 (95% CI: 1.4-3.7, p = 0.001)], after adjusting for age, gender, obesity, history of hypertension and diabetes, high CRP, high leukocyte count and glucocorticoid treatment in a multivariable logistic regression model.
Conclusions: Hypertriglyceridemia during hospitalization is independently associated with 2.3 times higher mortality in COVID-19 patients. Prospective studies are needed to independently validate this retrospective analysis.
Keywords: COVID-19 mortality; CRP; Diabetes; Inflammation; Leukocyte count; Obesity; Triglyceride; glucocorticoid.